BADERC-David Nathan

David Nathan, M.D.

Clinical Research in Type 1 and Type 2 Diabetes

Dr. David M. Nathan is an internationally recognized expert on diabetes and its complications. He is currently Director of the MGH Clinical Research Center (of the Harvard CTSC) and of the Diabetes Clinical Research Center at Massachusetts General Hospital. His major research focus is the study and development of new treatments of diabetes mellitus and the long-term consequences of such therapy. He has helped develop and investigated the role of the HbA1c assay in the diagnosis and management of diabetes, external and implantable pump therapy, and islet and whole organ transplantation for Type 1 diabetes, and new pharmacologic agents and hormones (e.g., GLP1) in the treatment of Type 2 diabetes. Dr. Nathan is an active participant in epidemiologic studies of diabetes and cardiovascular disease through the Framingham Heart Study, Nurses Health Study, and Baltimore Longitudinal Study of Aging. He was one of the architects of the Diabetes Control and Complications Trial, serving as Editor for DCCT publications. Dr. Nathan currently co-chairs the DCCT follow-up study, the Epidemiology of Diabetes Interventions and Complications Study, which is examining the long-term impact of diabetes and associated risk factors on micro- and macrovascular disease in Type 1 diabetes. He also is the Chairman of the Diabetes Prevention Program and Diabetes Prevention Program Outcome Study, NIH-sponsored multicenter trials that demonstrated the ability to prevent Type 2 diabetes and are continuing to examine the long-term outcomes of prevention of Type 2 diabetes, respectively. Dr. Nathan is also the Principal Investigator at the MGH of the LookAHEAD study and the TODAY study which are examining the long term impact of lifestyle interventions in Type 2 diabetes and the optimal therapy for Type 2 diabetes in adolescents and youth, respectively. Other studies focus on the translation of HbA1c into estimated average glucose (international A1c-Derived Average Glucose study, which Dr. Nathan chairs), the role of the A1C assay in the diagnosis of diabetes (International Expert Committee on the Diagnosis of Diabetes, chaired by DMN), the development of an artificial pancreas for the treatment of type 1 diabetes, an immune system directed intervention to halt the autoimmunity of type 1 diabetes, and studies that investigate new strategies to treat and prevent type 2 diabetes.

References:

Lorenzi M, Feke GT, Cagliero E, Pitler L, Schaumberg DA, Berisha F, Nathan DM, McMeel JW. Retinal haemodynamics in individuals with well-controlled type 1 diabetes. Diabetologia 2008; 51:361-4.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Update on thiazolidinediones. Diabetelogia 2008; 51: 8-11. (Published simultaneously in Diabetes Care 2008; 31: 173-5.
Pani L, Nathan DM, Grant RW. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1c < 7%. Diabetes Care 2008; 31: 386-90.
Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN for the DCCT/EDIC Research Group. The effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial—Revisited. Diabetes 2008; 57:995-1001.
Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008; 71:318-22.
Hivert MF, Sullivan LM, Fox CS, Nathan DM, D’Agosino RB Sr, Wilson PW, Meigs JB. Association of adiponectin, resistin, and TNF alpha with insulin resistance. J Clin Endo Metab 2008; 93:3165-72.
Crandall JP, Knowler WC, Kahn SF, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008; 4: 382-93.
Delahanty LM, Nathan DM. Implications of the Diabetes Prevention Program and LookAHEAD clinical trials for lifestyle interventions. J Am Diet Assoc. 2008; 108:S66-72.
Ginde AA, Cagliero E, Nathan DM, Camargo CA Jr. Point-of-care glucose and hemoglobin A1c in emergency department patients without known diabetes: implications for opportunistic screening. Acad Emerg Med 2008; PMID: 18785943.
Pani L, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, Sullivan L, D’Agostino RB, Nathan DM. Effect of aging on A1c levels in persons without diabetes. Evidence from the Framingham Offspring Study and NHANES 2001-2004. Diabetes Care 2008; 31: 1991-6.
Ginde AA, Cagliero E, Nathan DM, Camargo CA Jr. Value of risk stratification to increase the predictive validity of HbA1c in screening for undiagnosed diabetes in the US population. J Gen Intern Med 2008; 23: 1346-53.
Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ for the A1c Derived Average Glucose (ADAG) Study Group. Translating the A1c assay into estimated average glucose values. Diabetes Care 2008; 31: 1473-8.
Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, Nathan DM. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008; 34: 511-17.
Wexler DJ, Nathan DM, Grant RW, Regan S, Van Leuvan AL, Cagliero E. Prevalence of elevated HbA1c among patients admitted to the hospital without a diagnosis of diabetes. J Clin Endocrinol Metab 2008;93:4238-44.
Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, Nathan DM, Schaumberg DA. Inflammation and progressive nephropathy in type 1 diabetes mellitus in the Diabetes Control and Complications Trial (DCCT). Diabetes Care 2008; 31:2338-43.
Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM. Novel association of HKI with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study. PloS Genet 2008;4:e1000312. PMID: 19096518.
White NH, Sun W, Cleary PA, Danis RP, David MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126: 1707-15.
Nathan DM. How tight is right and how to get there. Arch Int Med 2008; 168:2064-6.
Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, Hanson RL, Shuldiner AR, Knowler WC, Altshuler D, Florez JC, Diabetes Prevention Program. Extension of type 2 diabetes genome-wide association scan results in the Diabetes Prevention Program. Diabetes 2008;57: 2503-10.
Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008; PMID: 18826999.
Al-Kateb H, Boright AP, Mirea L, Xie X, et al. and the DCCT/DIC Research Group. Multiple SOD1/SFRS15 variants are associated with the development and progression of diabetic nephropathy. Diabetes 2008;57: 218-28.
deBoer IH, Kestenbaum B, Rue Ts, et al. for the DCCT/EDIC Study Research Group. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Int Med 2008;168:1867-73.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetelogia 2009; 52: 17-30 PMID 18941734. (Published simultaneously in Diabetes Care 2009; 32: 192-203).
Nathan DM, Zinman B, Cleary PA, Backlund J-Y, Genuth S, Miller R, Orchard TJ for DCCT/EDIC Research Group. Modern Day Clinical Course of Type 1 Diabetes Mellitus after 30-years Duration. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) and Pittsburgh Epidemiology of Diabetes Complications (EDC) Experience 1983-2005. Arch Int Med 2009; in press.
Delahanty LM, Nathan DM, Lachin JM, Hu FB, Cleary PA, Ziegler GK, Wylie-Rosett J, Wexler D for the DCCT/EDIC Research Group. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am J Clin Nutr 2009; 89:518-24.






			David Nathan, M.D. Clinical Research in Type 1 and Type 2 Diabetes Dr. David M. Nathan is an internationally recognized expert on diabetes and its complications. He is currently Director of the MGH Clinical Research Center (of the Harvard CTSC) and of the Diabetes Clinical Research Center at Massachusetts General Hospital. His major research focus is the study and development of new treatments of diabetes mellitus and the long-term consequences of such therapy. He has helped develop and investigated the role of the HbA1c assay in the diagnosis and management of diabetes, external and implantable pump therapy, and islet and whole organ transplantation for Type 1 diabetes, and new pharmacologic agents and hormones (e.g., GLP1) in the treatment of Type 2 diabetes. Dr. Nathan is an active participant in epidemiologic studies of diabetes and cardiovascular disease through the Framingham Heart Study, Nurses Health Study, and Baltimore Longitudinal Study of Aging. He was one of the architects of the Diabetes Control and Complications Trial, serving as Editor for DCCT publications. Dr. Nathan currently co-chairs the DCCT follow-up study, the Epidemiology of Diabetes Interventions and Complications Study, which is examining the long-term impact of diabetes and associated risk factors on micro- and macrovascular disease in Type 1 diabetes. He also is the Chairman of the Diabetes Prevention Program and Diabetes Prevention Program Outcome Study, NIH-sponsored multicenter trials that demonstrated the ability to prevent Type 2 diabetes and are continuing to examine the long-term outcomes of prevention of Type 2 diabetes, respectively. Dr. Nathan is also the Principal Investigator at the MGH of the LookAHEAD study and the TODAY study which are examining the long term impact of lifestyle interventions in Type 2 diabetes and the optimal therapy for Type 2 diabetes in adolescents and youth, respectively. Other studies focus on the translation of HbA1c into estimated average glucose (international A1c-Derived Average Glucose study, which Dr. Nathan chairs), the role of the A1C assay in the diagnosis of diabetes (International Expert Committee on the Diagnosis of Diabetes, chaired by DMN), the development of an artificial pancreas for the treatment of type 1 diabetes, an immune system directed intervention to halt the autoimmunity of type 1 diabetes, and studies that investigate new strategies to treat and prevent type 2 diabetes. References: Lorenzi M, Feke GT, Cagliero E, Pitler L, Schaumberg DA, Berisha F, Nathan DM, McMeel JW. Retinal haemodynamics in individuals with well-controlled type 1 diabetes. Diabetologia 2008; 51:361-4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Update on thiazolidinediones. Diabetelogia 2008; 51: 8-11. (Published simultaneously in Diabetes Care 2008; 31: 173-5. Pani L, Nathan DM, Grant RW. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1c < 7%. Diabetes Care 2008; 31: 386-90. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN for the DCCT/EDIC Research Group. The effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial—Revisited. Diabetes 2008; 57:995-1001. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008; 71:318-22. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D’Agosino RB Sr, Wilson PW, Meigs JB. Association of adiponectin, resistin, and TNF alpha with insulin resistance. J Clin Endo Metab 2008; 93:3165-72. Crandall JP, Knowler WC, Kahn SF, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008; 4: 382-93. Delahanty LM, Nathan DM. Implications of the Diabetes Prevention Program and LookAHEAD clinical trials for lifestyle interventions. J Am Diet Assoc. 2008; 108:S66-72. Ginde AA, Cagliero E, Nathan DM, Camargo CA Jr. Point-of-care glucose and hemoglobin A1c in emergency department patients without known diabetes: implications for opportunistic screening. Acad Emerg Med 2008; PMID: 18785943. Pani L, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, Sullivan L, D’Agostino RB, Nathan DM. Effect of aging on A1c levels in persons without diabetes. Evidence from the Framingham Offspring Study and NHANES 2001-2004. Diabetes Care 2008; 31: 1991-6. Ginde AA, Cagliero E, Nathan DM, Camargo CA Jr. Value of risk stratification to increase the predictive validity of HbA1c in screening for undiagnosed diabetes in the US population. J Gen Intern Med 2008; 23: 1346-53. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ for the A1c Derived Average Glucose (ADAG) Study Group. Translating the A1c assay into estimated average glucose values. Diabetes Care 2008; 31: 1473-8. Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, Nathan DM. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008; 34: 511-17. Wexler DJ, Nathan DM, Grant RW, Regan S, Van Leuvan AL, Cagliero E. Prevalence of elevated HbA1c among patients admitted to the hospital without a diagnosis of diabetes. J Clin Endocrinol Metab 2008;93:4238-44. Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, Nathan DM, Schaumberg DA. Inflammation and progressive nephropathy in type 1 diabetes mellitus in the Diabetes Control and Complications Trial (DCCT). Diabetes Care 2008; 31:2338-43. Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM. Novel association of HKI with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study. PloS Genet 2008;4:e1000312. PMID: 19096518. White NH, Sun W, Cleary PA, Danis RP, David MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126: 1707-15. Nathan DM. How tight is right and how to get there. Arch Int Med 2008; 168:2064-6. Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, Hanson RL, Shuldiner AR, Knowler WC, Altshuler D, Florez JC, Diabetes Prevention Program. Extension of type 2 diabetes genome-wide association scan results in the Diabetes Prevention Program. Diabetes 2008;57: 2503-10. Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008; PMID: 18826999. Al-Kateb H, Boright AP, Mirea L, Xie X, et al. and the DCCT/DIC Research Group. Multiple SOD1/SFRS15 variants are associated with the development and progression of diabetic nephropathy. Diabetes 2008;57: 218-28. deBoer IH, Kestenbaum B, Rue Ts, et al. for the DCCT/EDIC Study Research Group. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Int Med 2008;168:1867-73. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetelogia 2009; 52: 17-30 PMID 18941734. (Published simultaneously in Diabetes Care 2009; 32: 192-203). Nathan DM, Zinman B, Cleary PA, Backlund J-Y, Genuth S, Miller R, Orchard TJ for DCCT/EDIC Research Group. Modern Day Clinical Course of Type 1 Diabetes Mellitus after 30-years Duration. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) and Pittsburgh Epidemiology of Diabetes Complications (EDC) Experience 1983-2005. Arch Int Med 2009; in press. Delahanty LM, Nathan DM, Lachin JM, Hu FB, Cleary PA, Ziegler GK, Wylie-Rosett J, Wexler D for the DCCT/EDIC Research Group. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am J Clin Nutr 2009; 89:518-24.